OnabotulinumtoxinA alters pro- and anti-inflammatory dural macrophage response to CSD in female mice

Aaron J Schain1,2, Diego Delgado Fajardo1, Andrew M Strassman1,2

  • 1Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Insights

Cortical spreading depression (CSD) activates meningeal macrophages. OnabotulinumtoxinA (onbotA) treatment in female mice reduced pro-inflammatory macrophages and increased anti-inflammatory ones, suggesting a novel therapeutic mechanism for migraine.

Area of Science:

  • Neuroscience
  • Immunology
  • Migraine Pathophysiology

Background:

  • Cortical spreading depression (CSD) is linked to migraine aura and activates dural nociceptive neurons and immune cells, particularly macrophages (MPs).
  • The mechanism of action for OnabotulinumtoxinA (onbotA), a chronic migraine treatment, remains incompletely understood.
  • Meningeal macrophages play a crucial role in the neuroinflammatory response during migraine.

Purpose of the Study:

  • To investigate the role of meningeal macrophages in a migraine model.
  • To determine the effect of OnabotulinumtoxinA (onbotA) on macrophage activation during CSD.
  • To explore potential sex-based differences in migraine pathophysiology and treatment response.

Main Methods:

  • Time-lapse in vivo multiphoton microscopy was used to assess meningeal macrophage activation based on shape changes.
  • CSD was induced to model migraine activation.
  • Macrophage responses were analyzed in female mice pre-treated with onbotA or saline.

Main Results:

  • CSD induction caused a subset of macrophages (∼10%) to contract processes, specifically in female mice, indicative of an M1-like response.
  • Lipopolysaccharide injection elicited a similar macrophage response, supporting the M1-like classification.
  • Interleukin-10 (IL-10) induced a subset of macrophages (∼10%) to expand processes (M2-like response), unaffected by CSD.
  • OnabotA pre-treatment in female mice significantly reduced overall macrophage numbers, decreased M1 pro-inflammatory responses, and increased M2 anti-inflammatory responses post-CSD compared to saline controls.

Conclusions:

  • OnabotA's therapeutic effect in chronic migraine may involve anti-inflammatory actions on the dural environment, beyond its effects on nociceptors.
  • Meningeal macrophages exhibit distinct responses to CSD and inflammatory stimuli, with potential sex-specific differences.
  • The findings suggest a novel mechanism for onbotA involving modulation of macrophage polarization in the dura mater.